EXACT SCIENCES CORP (EXAS)
US30063P1057 - Common Stock
Taking everything into account, EXAS scores 3 out of 10 in our fundamental rating. EXAS was compared to 565 industry peers in the Biotechnology industry. EXAS has a bad profitability rating. Also its financial health evaluation is rather negative. EXAS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
EXAS had negative earnings in the past year.
In the past year EXAS had a positive cash flow from operations.
EXAS had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
1.2 Ratios
EXAS's Return On Assets of -3.17% is amongst the best of the industry. EXAS outperforms 90.21% of its industry peers.
EXAS's Return On Equity of -6.67% is amongst the best of the industry. EXAS outperforms 91.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.17% | ||
| ROE | -6.67% | ||
| ROIC | N/A |
ROA(3y)-7.36%
ROA(5y)-8.98%
ROE(3y)-14.85%
ROE(5y)-18.14%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 72.96%, EXAS belongs to the top of the industry, outperforming 84.34% of the companies in the same industry.
In the last couple of years the Gross Margin of EXAS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.07%
GM growth 5Y-0.13%
2. Health
2.1 Basic Checks
EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EXAS has been increased compared to 1 year ago.
The number of shares outstanding for EXAS has been increased compared to 5 years ago.
Compared to 1 year ago, EXAS has a worse debt to assets ratio.
2.2 Solvency
EXAS has an Altman-Z score of 1.51. This is a bad value and indicates that EXAS is not financially healthy and even has some risk of bankruptcy.
EXAS has a Altman-Z score of 1.51. This is in the better half of the industry: EXAS outperforms 68.68% of its industry peers.
The Debt to FCF ratio of EXAS is 48.81, which is on the high side as it means it would take EXAS, 48.81 years of fcf income to pay off all of its debts.
EXAS has a Debt to FCF ratio of 48.81. This is amongst the best in the industry. EXAS outperforms 92.17% of its industry peers.
A Debt/Equity ratio of 0.73 indicates that EXAS is somewhat dependend on debt financing.
EXAS's Debt to Equity ratio of 0.73 is on the low side compared to the rest of the industry. EXAS is outperformed by 77.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 48.81 | ||
| Altman-Z | 1.51 |
ROIC/WACCN/A
WACC10.06%
2.3 Liquidity
EXAS has a Current Ratio of 2.12. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of EXAS (2.12) is worse than 74.38% of its industry peers.
EXAS has a Quick Ratio of 1.93. This is a normal value and indicates that EXAS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.93, EXAS is doing worse than 74.56% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
EXAS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.42%, which is quite impressive.
The Revenue has grown by 11.91% in the past year. This is quite good.
EXAS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.63% yearly.
EPS 1Y (TTM)26.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)11.91%
Revenue growth 3Y18.79%
Revenue growth 5Y40.63%
Sales Q2Q%12.78%
3.2 Future
The Earnings Per Share is expected to grow by 28.28% on average over the next years. This is a very strong growth
EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.32% yearly.
EPS Next Y-7.68%
EPS Next 2Y26.67%
EPS Next 3Y30.63%
EPS Next 5Y28.28%
Revenue Next Year10%
Revenue Next 2Y10.74%
Revenue Next 3Y11.07%
Revenue Next 5Y9.32%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EXAS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaper than 92.17% of the companies in the same industry.
EXAS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXAS is cheaper than 92.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 202.36 | ||
| EV/EBITDA | 1692.28 |
4.3 Compensation for Growth
EXAS's earnings are expected to grow with 30.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.67%
EPS Next 3Y30.63%
5. Dividend
5.1 Amount
EXAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EXACT SCIENCES CORP
NASDAQ:EXAS (12/26/2024, 12:15:44 PM)
57.87
-0.24 (-0.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.25%
Inst Owner Change2.59%
Ins Owners0.98%
Ins Owner Change0.61%
Market Cap10.71B
Analysts86.45
Price Target73.64 (27.25%)
Short Float %6.48%
Short Ratio4.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.77%
Min EPS beat(2)0.95%
Max EPS beat(2)72.6%
EPS beat(4)3
Avg EPS beat(4)22.35%
Min EPS beat(4)-26.5%
Max EPS beat(4)72.6%
EPS beat(8)7
Avg EPS beat(8)32.99%
EPS beat(12)10
Avg EPS beat(12)24.85%
EPS beat(16)11
Avg EPS beat(16)-49.56%
Revenue beat(2)0
Avg Revenue beat(2)-1.92%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.64%
Revenue beat(4)0
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)-0.37%
Revenue beat(8)3
Avg Revenue beat(8)0.99%
Revenue beat(12)7
Avg Revenue beat(12)1.62%
Revenue beat(16)11
Avg Revenue beat(16)1.79%
PT rev (1m)-9.15%
PT rev (3m)-6.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-875.67%
EPS NY rev (1m)-7.76%
EPS NY rev (3m)-24.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.97%
Revenue NY rev (1m)-0.53%
Revenue NY rev (3m)-3.22%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.98 | ||
| P/FCF | 202.36 | ||
| P/OCF | 45.97 | ||
| P/B | 3.34 | ||
| P/tB | N/A | ||
| EV/EBITDA | 1692.28 |
EPS(TTM)-1.17
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)0.29
FCFY0.49%
OCF(TTM)1.26
OCFY2.18%
SpS14.55
BVpS17.35
TBVpS-5.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.17% | ||
| ROE | -6.67% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.96% | ||
| FCFM | 1.97% |
ROA(3y)-7.36%
ROA(5y)-8.98%
ROE(3y)-14.85%
ROE(5y)-18.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.07%
GM growth 5Y-0.13%
F-Score5
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.73 | ||
| Debt/FCF | 48.81 | ||
| Debt/EBITDA | 332.38 | ||
| Cap/Depr | 83.39% | ||
| Cap/Sales | 6.69% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 3317.56% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 1.51 |
F-Score5
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)92.13%
Cap/Depr(5y)182.37%
Cap/Sales(3y)8.75%
Cap/Sales(5y)15.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-7.68%
EPS Next 2Y26.67%
EPS Next 3Y30.63%
EPS Next 5Y28.28%
Revenue 1Y (TTM)11.91%
Revenue growth 3Y18.79%
Revenue growth 5Y40.63%
Sales Q2Q%12.78%
Revenue Next Year10%
Revenue Next 2Y10.74%
Revenue Next 3Y11.07%
Revenue Next 5Y9.32%
EBIT growth 1Y20.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year249.42%
EBIT Next 3Y67.93%
EBIT Next 5Y44.21%
FCF growth 1Y110.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y177.64%
OCF growth 3Y4.58%
OCF growth 5YN/A